ArticleMolecular psychiatry2025
Peripartum sertraline impacts maternal neurobehavioral and neurodegenerative mechanisms in pregnant and postpartum mice.
Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Renovating the Barnes maze for mouse models of dementia with STARR FIELD: A 4-day protocol for learning rate, retention, and cognitive flexibility.Methods (San Diego, Calif.) · 2026Article
- Evaluation of Vortioxetine on Global DNA Methylation in Maternal and Offspring Rats and In Silico Molecular Docking to Key Epigenetic Enzymes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Selective Serotonin Reuptake Inhibitors (SSRIs) are among the most common medications used for depression in postpartum and lactating people, who experience increased depression risk. However, there is a limited understanding of peripartum SSRI impacts on maternal neurobehavioral responses, and particularly those of sertraline, the most prescribed SSRI in United States (US) pregnancies. We administered C57Bl/6 females sertraline via a non-invasive, naturalistic approach (167 mg/L drinking water) from 2 weeks pre-conception through lactation (PND21) or for an equivalent duration in nonpregnant controls. We assessed behavior and molecular brain changes intrapartum and postpartum at ~1 year of age. Chronic sertraline reduced depressive- and anxiety-like behaviors. Pregnancy itself decreased anxiety-like and hedonic behaviors. RNA sequencing of maternal brain revealed only 52 differentially expressed genes (DEGs) in frontal cortex with sertraline. These DEGs over-represented functions related to immunity. In contrast, sertraline altered 962 targets in maternal hypothalamic paraventricular nucleus, with DEGs overrepresenting neurotransmission and neurodegeneration. We then discontinued sertraline and aged animals to approximately 1 year to test neurodegenerative phenotypes. Having one prior litter, regardless of peripartum sertraline, improved aged females' spatial learning and memory. Sertraline, regardless of postpartum status, improved working memory. Further, we found buffering of neurodegeneration-related gene network changes and increased excitatory synapse density in the hippocampus after peripartum sertraline. Peripartum sertraline alters maternal neurobiology and behavior in pregnancy and beyond, with long-term benefits to neurodegenerative processes. Pregnancy also exerts its own, lasting effects on learning and memory. These findings might be exploited in the future to abrogate neurodegenerative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.